Pirfenidone Dose Adjustment for Liver Function Abnormalities
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pirfenidone administration can lead to abnormal liver function, indicated by elevated biomarkers, posing a challenge in maintaining effective treatment for patients with idiopathic pulmonary fibrosis and other fibrotic conditions without causing hepatotoxicity.
Innovation Solution
Administering pirfenidone at reduced doses or temporarily discontinuing it until liver function biomarkers return to normal levels, followed by gradual re-escalation to the full target dose, allowing continued treatment while monitoring liver function to maximize therapeutic benefits and minimize liver injury.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pirfenidone is administered at full target dose to treat fibrosis, then therapeutic effect is improved, but abnormal liver function occurs
Solution Approach 1:
The patent implements dynamic dose adjustment of pirfenidone based on liver function monitoring. Patients receive full target dose (2400-2600 mg/day) when liver enzymes are normal, but the dose is temporarily reduced or discontinued when transaminases elevate, then gradually re-escalated when liver function returns to normal. This dynamic approach maintains maximum therapeutic benefit while preventing hepatotoxicity.
Solution Approach 2:
The patent changes the dosage parameter of pirfenidone based on liver function status. The dose is adjusted between full target dose (2400-2600 mg/day) and reduced/discontinued state according to transaminase levels. This parameter change allows the treatment to adapt to the patient's liver tolerance, resolving the contradiction between maintaining therapeutic effect and preventing liver injury.
2Object-affected harmful factors
If pirfenidone dose is reduced to avoid liver injury, then liver safety is improved, but therapeutic effect decreases
Solution Approach 1:
The patent implements periodic monitoring of liver function enzymes during pirfenidone treatment. Based on these periodic assessments, the dose is temporarily reduced or discontinued when abnormalities occur, then restored when liver function normalizes. This periodic action pattern allows the patient to receive maximum therapeutic benefit over the treatment course while preventing cumulative liver injury.
Solution Approach 2:
The patent performs preliminary assessment of liver function before initiating full-dose pirfenidone treatment and continues monitoring throughout therapy. When transaminase elevations are detected, dose reduction is implemented preventively before significant liver injury can occur. This preliminary and ongoing monitoring approach protects liver safety while maintaining therapeutic efficacy.
Data Source
AI summary
Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.